Waterfront Wealth Inc. Purchases 200 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Waterfront Wealth Inc. grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,075 shares of the medical equipment provider’s stock after buying an additional 200 shares during the period. Waterfront Wealth Inc.’s holdings in Zimmer Biomet were worth $1,226,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of ZBH. Clear Street Markets LLC acquired a new stake in Zimmer Biomet in the 4th quarter worth approximately $27,000. Dark Forest Capital Management LP acquired a new stake in Zimmer Biomet in the 1st quarter worth approximately $35,000. Lazard Asset Management LLC boosted its stake in Zimmer Biomet by 70.5% in the 3rd quarter. Lazard Asset Management LLC now owns 283 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 117 shares in the last quarter. Activest Wealth Management boosted its stake in Zimmer Biomet by 410.4% in the 4th quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 275 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in Zimmer Biomet by 67.1% in the 2nd quarter. Farther Finance Advisors LLC now owns 351 shares of the medical equipment provider’s stock worth $51,000 after purchasing an additional 141 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Price Performance

NYSE ZBH traded down $0.77 on Wednesday, hitting $121.30. The company had a trading volume of 1,520,357 shares, compared to its average volume of 1,484,111. The company has a market capitalization of $24.92 billion, a PE ratio of 24.81, a PEG ratio of 2.28 and a beta of 1.01. The company’s fifty day moving average price is $126.47 and its 200-day moving average price is $119.10. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.61 and a quick ratio of 0.78. Zimmer Biomet Holdings, Inc. has a 12-month low of $102.00 and a 12-month high of $149.25.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.15 by $0.05. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The company had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.93 billion. During the same quarter in the previous year, the company posted $1.88 EPS. The firm’s quarterly revenue was up 6.3% on a year-over-year basis. As a group, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a dividend of $0.24 per share. The ex-dividend date is Wednesday, March 27th. This represents a $0.96 annualized dividend and a yield of 0.79%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 19.63%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on ZBH shares. Truist Financial lifted their target price on shares of Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a research note on Friday, February 9th. TheStreet raised shares of Zimmer Biomet from a “c” rating to a “b-” rating in a research report on Thursday, February 8th. Raymond James raised their price target on shares of Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Citigroup raised their price target on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. Finally, StockNews.com lowered shares of Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 19th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and a consensus price target of $139.39.

Insiders Place Their Bets

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of Zimmer Biomet stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the sale, the vice president now owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.70% of the stock is currently owned by corporate insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.